Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. more
Time Frame | MESO | Sector | S&P500 |
---|---|---|---|
1-Week Return | 61.54% | -3.35% | -2.97% |
1-Month Return | 54.9% | -3.49% | -0.66% |
3-Month Return | 161.47% | -12.6% | 2.71% |
6-Month Return | 133.1% | -6.91% | 7.21% |
1-Year Return | 690.57% | 1.19% | 23.04% |
3-Year Return | 76.05% | -0.21% | 28.43% |
5-Year Return | 19.2% | 33.09% | 82.88% |
10-Year Return | -53.15% | 93.55% | 184.63% |
Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 32.16M | 7.46M | 10.21M | 7.50M | 5.90M | [{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":23.19,"profit":true},{"date":"2022-06-30","value":31.75,"profit":true},{"date":"2023-06-30","value":23.33,"profit":true},{"date":"2024-06-30","value":18.35,"profit":true}] |
Cost of Revenue | 25.31M | 32.72M | 30.76M | 27.73M | 15.72M | [{"date":"2020-06-30","value":77.35,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":94,"profit":true},{"date":"2023-06-30","value":84.76,"profit":true},{"date":"2024-06-30","value":48.04,"profit":true}] |
Gross Profit | 6.85M | (25.26M) | (20.55M) | (20.23M) | (9.81M) | [{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":-368.96,"profit":false},{"date":"2022-06-30","value":-300.07,"profit":false},{"date":"2023-06-30","value":-295.49,"profit":false},{"date":"2024-06-30","value":-143.35,"profit":false}] |
Gross Margin | 21.29% | (338.83%) | (201.21%) | (269.72%) | (166.30%) | [{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":-1591.26,"profit":false},{"date":"2022-06-30","value":-944.98,"profit":false},{"date":"2023-06-30","value":-1266.72,"profit":false},{"date":"2024-06-30","value":-781,"profit":false}] |
Operating Expenses | 107.56M | 115.06M | 90.78M | 76.79M | 5.90M | [{"date":"2020-06-30","value":93.48,"profit":true},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":78.9,"profit":true},{"date":"2023-06-30","value":66.74,"profit":true},{"date":"2024-06-30","value":5.13,"profit":true}] |
Operating Income | (79.07M) | (111.87M) | (80.95M) | (69.14M) | (58.79M) | [{"date":"2020-06-30","value":-7907200000,"profit":false},{"date":"2021-06-30","value":-11186700000,"profit":false},{"date":"2022-06-30","value":-8095300000,"profit":false},{"date":"2023-06-30","value":-6913600000,"profit":false},{"date":"2024-06-30","value":-5879400000,"profit":false}] |
Total Non-Operating Income/Expense | (23.00M) | (1.25M) | (28.30M) | (32.10M) | (48.19M) | [{"date":"2020-06-30","value":-2299900000,"profit":false},{"date":"2021-06-30","value":-124800000,"profit":false},{"date":"2022-06-30","value":-2829700000,"profit":false},{"date":"2023-06-30","value":-3210300000,"profit":false},{"date":"2024-06-30","value":-4818700000,"profit":false}] |
Pre-Tax Income | (87.36M) | (99.63M) | (91.59M) | (82.10M) | (88.15M) | [{"date":"2020-06-30","value":-8735500000,"profit":false},{"date":"2021-06-30","value":-9963000000,"profit":false},{"date":"2022-06-30","value":-9158600000,"profit":false},{"date":"2023-06-30","value":-8210100000,"profit":false},{"date":"2024-06-30","value":-8814700000,"profit":false}] |
Income Taxes | (9.41M) | (819.00K) | (239.00K) | (212.00K) | (191.00K) | [{"date":"2020-06-30","value":-941500000,"profit":false},{"date":"2021-06-30","value":-81900000,"profit":false},{"date":"2022-06-30","value":-23900000,"profit":false},{"date":"2023-06-30","value":-21200000,"profit":false},{"date":"2024-06-30","value":-19100000,"profit":false}] |
Income After Taxes | (77.94M) | (98.81M) | (91.35M) | (81.89M) | (87.96M) | [{"date":"2020-06-30","value":-7794000000,"profit":false},{"date":"2021-06-30","value":-9881100000,"profit":false},{"date":"2022-06-30","value":-9134700000,"profit":false},{"date":"2023-06-30","value":-8188900000,"profit":false},{"date":"2024-06-30","value":-8795600000,"profit":false}] |
Income From Continuous Operations | (77.94M) | (98.81M) | (91.35M) | (81.89M) | (87.96M) | [{"date":"2020-06-30","value":-7794000000,"profit":false},{"date":"2021-06-30","value":-9881100000,"profit":false},{"date":"2022-06-30","value":-9134700000,"profit":false},{"date":"2023-06-30","value":-8188900000,"profit":false},{"date":"2024-06-30","value":-8795600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Net Income | (77.94M) | (98.81M) | (91.35M) | (81.89M) | (87.96M) | [{"date":"2020-06-30","value":-7794000000,"profit":false},{"date":"2021-06-30","value":-9881100000,"profit":false},{"date":"2022-06-30","value":-9134700000,"profit":false},{"date":"2023-06-30","value":-8188900000,"profit":false},{"date":"2024-06-30","value":-8795600000,"profit":false}] |
EPS (Diluted) | (0.74) | (0.82) | (0.70) | (0.55) | - | [{"date":"2020-06-30","value":-74,"profit":false},{"date":"2021-06-30","value":-82,"profit":false},{"date":"2022-06-30","value":-70,"profit":false},{"date":"2023-06-30","value":-54.74,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
MESO | |
---|---|
Cash Ratio | 0.85 |
Current Ratio | 1.18 |
Quick Ratio | 1.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MESO | |
---|---|
ROA (LTM) | -5.41% |
ROE (LTM) | -17.91% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MESO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.28 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.72 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MESO | |
---|---|
Trailing PE | NM |
Forward PE | 454.55 |
P/S (TTM) | 241.90 |
P/B | 2.97 |
EV/R | 137.12 |
EV/Ebitda | NM |
PEG | NM |
Mesoblast Ltd (MESO) share price today is $16.76
Yes, Indians can buy shares of Mesoblast Ltd (MESO) on Vested. To buy Mesoblast Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MESO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Mesoblast Ltd (MESO) via the Vested app. You can start investing in Mesoblast Ltd (MESO) with a minimum investment of $1.
You can invest in shares of Mesoblast Ltd (MESO) via Vested in three simple steps:
The 52-week high price of Mesoblast Ltd (MESO) is $13.74. The 52-week low price of Mesoblast Ltd (MESO) is $1.61.
The price-to-earnings (P/E) ratio of Mesoblast Ltd (MESO) is
The price-to-book (P/B) ratio of Mesoblast Ltd (MESO) is 2.97
The dividend yield of Mesoblast Ltd (MESO) is 0.00%
The market capitalization of Mesoblast Ltd (MESO) is $1.14B
The stock symbol (or ticker) of Mesoblast Ltd is MESO